Skip to main content
SpringerLink
Log in

Long-Term Effects of Amino-Bisphosphonates on Circulating γδ T Cells

  • Original Research
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Abstract

The aim of this study was to explore whether desensitization to the occurrence of the acute-phase response (APR) in patients previously treated with amino-bisphosphonates (N-BPs) is due to a long-lasting reduction in the number of circulating γδ T cells. Circulating lymphocyte subpopulation counts were obtained from 63 patients with postmenopausal or senile osteoporosis at baseline and after 2 days and 12 months of the first intravenous (IV) 5 mg zoledronic acid (ZOL) infusion. At baseline both the proportion and absolute number of circulating γδ T cells were significantly higher in patients who had never used N-BPs vs. previous users, either oral or IV. A typical APR was observed in none of the patients given IV ZOL a year earlier, in 6 (22 %) of the patients previously treated with oral N-BPs, and in 13 (57 %) of the patients naive to any N-BP treatment. In patients naive to N-BPs, a significant reduction in both total lymphocytes and their subsets was observed 2 days after ZOL infusion; all these changes returned to baseline values 1 year later with the exception of γδ T cells, which remained significantly lower in terms of both proportion and absolute number. These results indicate for the first time that both IV and oral N-BP treatments are associated with a long-lasting decrease in circulating γδ T cells, and this may explain the lower incidence of APR in patients previously exposed to N-BPs. Other clinical implications of this sustained effect of N-BPs on immune-regulatory cells might be important.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V (1987) The acute-phase response after bisphoshonate administration. Calcif Tissue Int 41:326–333

    Article  PubMed  CAS  Google Scholar 

  2. Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Lowik CW, Papapoulos SE (1995) Interleukin-6 and the acute phase response during treatment of patients with Paget’s disease with the nitrogen-containing bisphosphonate dimethyl-amino-hydroxy-propylidene bisphosphonate. J Bone Miner Res 10:956–962

    Article  PubMed  CAS  Google Scholar 

  3. Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D (1996) Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18:133–139

    Article  PubMed  CAS  Google Scholar 

  4. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K (2009) Peripheral blood monocytes are responsible for gamma delta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 144:245–250

    Article  PubMed  Google Scholar 

  5. Thompson K, Rogers MJ (2004) Statins prevent bisphosphonate-induced T-cell proliferation and activation in vitro. J Bone Miner Res 19:278–288

    Article  PubMed  CAS  Google Scholar 

  6. Kunzmann V, Bauer E, Wilhelm M (1999) Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 340:737–738

    Article  PubMed  CAS  Google Scholar 

  7. Kunzmann V, Bauer E, Feurle J, Weibinger F, Tony HP, Wilhelm M (2000) Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384–392

    PubMed  CAS  Google Scholar 

  8. Das H, Wang L, Kamath A, Bukowski JF (2001) Vγ2Vδ2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98:1616–1618

    Article  PubMed  CAS  Google Scholar 

  9. Thompson K, Rogers MJ (2006) Bisphosphonates and γδ T-cells: new insights into old drugs. BoneKEy Osteovision 3:5–14

    Article  Google Scholar 

  10. Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380–4387

    Article  PubMed  CAS  Google Scholar 

  11. Rossini M, Adami S, Viapiana O, Ortolani R, Vella A, Fracassi E, Gatti D (2012) Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration. J Bone Miner Res 27:227–230

    Article  CAS  Google Scholar 

  12. Argentati K, Re F, Donnini A, Tucci MG, Franceschi C, Bartozzi B, Bernardini G, Provinciali M (2002) Numerical and functional alterations of circulating γδ T lymphocytes in aged people and centenarians. J Leukoc Biol 72:65–71

    PubMed  CAS  Google Scholar 

  13. Caccamo N, Dieli F, Wesch D, Jornaa H, Eberl M (2006) Sex-specific phenotypical and functional differences in peripheral human Vγ9/Vδ2 T cells. J Leukoc Biol 79:663–666

    Article  PubMed  CAS  Google Scholar 

  14. Dieli F, Vermijlen D, Fulfaro F, Caccamo N, Meraviglia S, Cicero G, Roberts A, Buccheri A, D’Asaro M, Gebbia N, Salerno A, Eberl M, Hayday AC (2007) Targeting human gammadelta T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 67:7450–7457

    Article  PubMed  CAS  Google Scholar 

  15. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP (2003) Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102:200–206

    Article  PubMed  CAS  Google Scholar 

  16. Srivastava T, Haney CJ, Alon US (2009) Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. J Bone Miner Res 24:334–337

    Article  PubMed  Google Scholar 

  17. Thompson K, Keech F, McLernon DJ, Vinod K, May RJ, Simpson WG, Rogers MJ, Reid DM (2011) Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women. Bone 49:140–145

    Article  PubMed  CAS  Google Scholar 

  18. Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C, Sireci G, Salerno A (2003) Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102:2310–2311

    Article  PubMed  CAS  Google Scholar 

  19. Lymperi S, Ersek A, Ferraro F, Dazzi F, Horwood NJ (2011) Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood 117:1540–1549

    Article  PubMed  CAS  Google Scholar 

  20. Kabelitz D, Wesch D, He W (2007) Perspectives of human γδ T cells in tumor immunology. Cancer Res 67:5–8

    Article  PubMed  CAS  Google Scholar 

  21. Rennert G, Pinchev M, Rennert HS (2010) Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 28:3577–3581

    Article  PubMed  CAS  Google Scholar 

  22. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S, O’Sullivan MJ, Safford M, Hendrix SL, Wallace RB (2010) Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol 28:3582–3590

    Article  PubMed  CAS  Google Scholar 

  23. Rennert G, Pinchev M, Rennert HS, Gruber SB (2011) Use of bisphosphonate and reduced risk of colorectal cancer. J Clin Oncol 29:1146–1150

    Article  PubMed  Google Scholar 

  24. Kamiya N, Suzuki H, Endo T, Takano M, Yano M, Naoi M, Nishimi D, Kawamura K, Imamoto T, Ichikawa T (2011) Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade. Int J Urol 19:169–173

    Article  PubMed  Google Scholar 

  25. Sendur MA, Aksoy S, Yaman S, Ank Z, Ozdemir NY, Zengin N, Altundag K (2012) Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use. Med Oncol. doi:10.1007/s12032-012-0209-9

Download references

Author information

Authors and Affiliations

  1. Rheumatology Unit, Department of Medicine, University of Verona, Policlinico Borgo Roma, Piazzale Scuro, 10, 37134, Verona, Italy

    Maurizio Rossini, Silvano Adami, Ombretta Viapiana, Elena Fracassi, Gaia Tripi, Luca Idolazzi & Davide Gatti

  2. Hematology Section, Department of Medicine, University of Verona, Verona, Italy

    Roberta Zanotti

  3. Immunology Unit, Department of Pathology, University Hospital, Verona, Italy

    Riccardo Ortolani & Antonio Vella

Authors
  1. Maurizio Rossini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvano Adami
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ombretta Viapiana
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elena Fracassi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Riccardo Ortolani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Antonio Vella
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Roberta Zanotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gaia Tripi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Luca Idolazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Davide Gatti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Silvano Adami.

Additional information

The authors have stated that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rossini, M., Adami, S., Viapiana, O. et al. Long-Term Effects of Amino-Bisphosphonates on Circulating γδ T Cells. Calcif Tissue Int 91, 395–399 (2012). https://doi.org/10.1007/s00223-012-9647-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-012-9647-9

Keywords

Search

Navigation